The information contained in this study is provided for educational and informational purposes only, and should not be construed as suggesting, implying, establishing or making claims in any manner or respect regarding the safety, efficacy or therapeutic benefit of any of ZooPharm’s compounded drug preparations. Any such claims can only be made with respect to drugs that have been tested in accordance with studies and labels approved by the United States Food and Drug Administration. ZooPharm is a compounding pharmacy whose preparations, by law, are not required to go through FDA’s new drug approval process and, therefore, have not been tested for safety and efficacy. ZooPharm does not and should not be construed to make any safety, efficacy or other health claims about its compounded drug preparations and any implication to the contrary is specifically disavowed. The information contained in this study is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a practitioner with any questions you may have regarding a medical condition or the medications used to treat it.
Conducted: December, 2015 – February, 2016 Location: Apple Creek Ranch, Gillett, Wisconsin Investigators: Stephen Kirschner, MSc, Ryan Rodenkirch, BS Study Director: William R. Lance, DVM, MS, PhD, DACZM
This study was designed to evaluate the quality of anesthesia produced by a combination of
butorphanol-azaperone-medetomidine (BAM), as compared to tiletamine /zolazepam HClxylazine [T/X]. Key physiological parameters and sperm viability criteria were also compared from
electroejaculated sperm samples collected using the two anesthesia combinations described.
Animals: Single treatment group of 10 mature male deer ranging from1-4 years of age.
Experimental Design: Single, two-treatment crossover design protocol with semen collected
from each buck, with a 4-week washout period between collection phases as follows:
A total of 11 reproductive parameters for sperm were quantified during the study. Assessments included: total seminal volume; sperm concentration; total sperm number; % of progressively motile sperm; and total number of viable sperm. In addition, sperm motion and velocity parameters including curvilinear velocity (VCL), straight line velocity (VSL), average path velocity (VAP), linearity (LIN=VSL/VCL), and straightness (STR=VSL/VAP) were evaluated on all semen samples using computer-aided sperm analysis (CASA).
Analysis of Anesthesia Efficacy
Comparative results observed between these two anesthetic protocols were as follows:
1. Equivalent mean semen volumes were collected when anesthetizing with BAM or T/X.
2. Mean body temperatures recorded under BAM or T/X anesthesia were also statistically equivalent.
3. Significant variations in both pulse rate and respiration rate were observed between the BAM versus T/X collections. a. Recorded mean heart rates (bpm) while under BAM anesthesia were ~10% lower than when collecting following T/X immobilization. b. Respiration measurement under BAM anesthesia generated mean breaths per minute data ~21% lower than while under T/X
4. Comparison of quantitative reversal times recorded following collection (duration until no-sign-of sedation is observed) was determined to be 3.5 minutes following BAM reversal, as compared to a mean value of 48.3 minutes when recovering from T/X anesthesia
Evaluation of Sperm Quality and Viability
Table below presents key sperm parameters as assessed for each animal collected, comparing BAM to T/X anesthesia immobilizations. Our results show that sperm from test group males immobilized with BAM anesthesia, varied markedly versus T/X-anesthetized collections from the same animals in several of the sperm viability criteria and functional characteristics. In fact, several previously published studies have indicated how variations in collection procedure could lead to changes in the composition of the ejaculate in ruminants, resulting in different structural and functional characteristics affecting affect overall fertility potential. 1,2,3
©Wildlife Pharmaceuticals, Inc. 2016 Email: info@wildpharm.com